Akebia Therapeutics Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
194
- Stock Symbol
-
AKBA
- Investments
-
4
- Share Price
-
$0.47
- (As of Friday Closing)
Akebia Therapeutics General Information
Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Contact Information
Website
www.akebia.comCorporate Office
- 245 First Street
- Suite 1400
- Cambridge, MA 02142
- United States
Corporate Office
- 245 First Street
- Suite 1400
- Cambridge, MA 02142
- United States
Akebia Therapeutics Stock Performance
As of 13-Nov-2026, Akebia Therapeutics’s stock price is $0.47. Its current market cap is $132M with 278M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.47 | $0.50 | $0.36 - $1.83 | $132M | 278M | 8.13M | -$0.17 |
Akebia Therapeutics Financials Summary
As of 30-Sep-2026, Akebia Therapeutics has a trailing 12-month revenue of $197M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 154,359 | 313,372 | 429,106 | 244,775 |
| Revenue | 197,197 | 236,196 | 160,180 | 194,623 |
| EBITDA | (26,114) | 21,727 | (13,721) | (8,266) |
| Net Income | (44,560) | (5,345) | (69,410) | (51,925) |
| Total Assets | 342,127 | 376,565 | 220,670 | 241,703 |
| Total Debt | 60,491 | 51,798 | 47,640 | 48,121 |
Akebia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akebia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Akebia Therapeutics Comparisons
Industry
Financing
Details
Akebia Therapeutics Competitors (68)
One of Akebia Therapeutics’s 68 competitors is Travere Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Travere Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Calliditas Therapeutics | Formerly VC-backed | Stockholm, Sweden | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Mesoblast | Corporation | Melbourne, Australia | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
Akebia Therapeutics Patents
Akebia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024407543-A1 | Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use | Pending | 19-Dec-2023 | ||
| EP-4828662-A1 | Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use | Pending | 19-Dec-2023 | ||
| WO-2025137158-A1 | Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use | Inactive | 19-Dec-2023 | ||
| AU-2024373907-A1 | Treatment of anca-associated vasculitis | Pending | 30-Oct-2023 | ||
| EP-4801531-A1 | Treatment of anca-associated vasculitis | Pending | 30-Oct-2023 | A61P13/12 |
Akebia Therapeutics Signals
Akebia Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Akebia Therapeutics Investments & Acquisitions (4)
Akebia Therapeutics’s most recent deal was a Corporate Asset Purchase with Q32 Bio (Phase 2 Complement Inhibitor Adx-097) for . The deal was made on 01-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Q32 Bio (Phase 2 Complement Inhibitor Adx-097) | 01-Dec-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Cyclerion Therapeutics (Rights to Develop and Commercialize Praliciguat) | 04-Jun-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Keryx Biopharmaceuticals | 13-Dec-2018 | Merger/Acquisition | Pharmaceuticals | ||
| Janssen Pharmaceutica (hypoxia-inducible factor) | 13-Feb-2017 | Corporate Asset Purchase | Buildings and Property |
Akebia Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
29.55 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Akebia Therapeutics FAQs
-
When was Akebia Therapeutics founded?
Akebia Therapeutics was founded in 2007.
-
Where is Akebia Therapeutics headquartered?
Akebia Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Akebia Therapeutics?
Akebia Therapeutics has 194 total employees.
-
What industry is Akebia Therapeutics in?
Akebia Therapeutics’s primary industry is Pharmaceuticals.
-
Is Akebia Therapeutics a private or public company?
Akebia Therapeutics is a Public company.
-
What is Akebia Therapeutics’s stock symbol?
The ticker symbol for Akebia Therapeutics is AKBA.
-
What is the current stock price of Akebia Therapeutics?
As of 13-Nov-2026 the stock price of Akebia Therapeutics is $0.47.
-
What is the current market cap of Akebia Therapeutics?
The current market capitalization of Akebia Therapeutics is $132M.
-
What is Akebia Therapeutics’s current revenue?
The trailing twelve month revenue for Akebia Therapeutics is $197M.
-
Who are Akebia Therapeutics’s competitors?
Travere Therapeutics, Calliditas Therapeutics, AB Science, Mesoblast, and Gilead are some of the 68 competitors of Akebia Therapeutics.
-
What is Akebia Therapeutics’s annual earnings per share (EPS)?
Akebia Therapeutics’s EPS for 12 months was -$0.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process